NCT00301535View on ClinicalTrials.gov

A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions
Coronary Artery Disease
Interventions
DRUG

HBOC-201 (hemoglobin glutamer-250 bovine)

HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL

Trial Locations (3)

552 36

RECRUITING

Thessaloniki Heart Institute - St. Luke's Hospital, Thessaloniki

Unknown

RECRUITING

Milpark Hospital, Johannesburg

OX3 9DU

RECRUITING

Oxford Heart Centre - John Radcliffe Hospital, Headington

Sponsors
All Listed Sponsors
lead

Biopure Corporation

INDUSTRY

NCT00301535 - A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery | Biotech Hunter | Biotech Hunter